The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibodys latest Press releases

2022-05-03

Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Solna, Sweden, Los Angeles,...[read more]

2022-04-20

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)...[read more]

2022-03-07

RallyBio Announces Phase 1 Initiation with RLYB116...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies